We hypothesized that after penetrating through the newly developed tumor blood vessels with relatively loose endothelial spaces [18], the LHRH-NB loading with the drugs could then remain in the ovarian cancer tissues and cell surface for a long time. This evidence concerns the gene GNRH1 and ovarian carcinoma.